866-997-4948 (US-Canada Toll Free)

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : 2013-04-17

Category :

Healthcare

No. of Pages : 138

Product Synopsis


Global Markets Directs, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. 

It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma.
  • A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Content

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cutaneous T-Cell Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Cutaneous T-Cell Lymphoma 10
Cutaneous T-Cell Lymphoma Therapeutics under Development by Companies 12
Cutaneous T-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Cutaneous T-Cell Lymphoma Therapeutics - Products under Development by Companies 20
Cutaneous T-Cell Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Cutaneous T-Cell Lymphoma Therapeutics Development 23
Johnson & Johnson 23
Kyowa Hakko Kirin Co., Ltd. 24
Shionogi & Co., Ltd. 25
Seattle Genetics, Inc. 26
Emergent BioSolutions Inc. 27
Novartis AG 28
Eisai Co., Ltd. 29
Onyx Pharmaceuticals, Inc. 30
Mundipharma International Limited 31
Innate Pharma SA 32
Spectrum Pharmaceuticals, Inc. 33
Mondobiotech Holding AG 34
Yaupon Therapeutics, Inc. 35
ELORAC, Inc. 36
Cutaneous T-Cell Lymphoma - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
brentuximab vedotin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
panobinostat - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
carfilzomib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
everolimus - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
mogamulizumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
forodesine hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
mechlorethamine hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pralatrexate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IPH-41 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
zanolimumab - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
belinostat + [bortezomib] - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
everolimus + panobinostat - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Therapeutic allogeneic lymphocytes program - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
quisinostat - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
bexarotene - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
alefacept - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
naloxone hydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
DasKloster-011201 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
DNA IL-12 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
[pralatrexate] + [bexarotene] - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SHP-141 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Angeloxin - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
resiquimod - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Genetically Modified T Cells 1138 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
interferon gamma-1a - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates 95
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products 125
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 126
Cutaneous T-Cell Lymphoma - Product Development Milestones 128
Featured News & Press Releases 128
Nov 15, 2012: Elorac Obtains European Orphan Medical Product Designation For Naloxone Hydrochloride Dehydrate For Treatment Of Cutaneous T-cell Lymphoma 128
Nov 05, 2012: Seattle Genetics To Present Data On Adcetris And Antibody-Drug Conjugates At American Society Of Hematology Annual Meeting 128
Jul 09, 2012: OncoSec Initiates Phase II Clinical Program In Cutaneous T-Cell Lymphoma And Doses First Patient 130
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 131
Jun 05, 2012: Ceptaris Receives Complete Response Letter From FDA For Mechlorethamine Gel 131
May 10, 2012: Seattle Genetics Presents Interim Results From Phase II Trial Of ADCETRIS At Society For Investigative Dermatology Annual Meeting 131
Jan 26, 2012: Seattle Genetics Announces Data From ADCETRIS In Cutaneous T-Cell Lymphoma And Peripheral T-Cell Lymphoma 132
Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity 134
Jan 18, 2012: Ceptaris Receives Orphan Drug Designation From EMA For Mechlorethamine Gel 134
Oct 04, 2011: FDA Accepts Filing Of NDA For Yaupongel's Gel Formulation Of Mechlorethamine Hydrochloride 135

Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 137
Disclaimer 137

List of Tables


Number of Products Under Development for Cutaneous T-Cell Lymphoma, H1 2013 10
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Johnson & Johnson, H1 2013 23
Kyowa Hakko Kirin Co., Ltd., H1 2013 24
Shionogi & Co., Ltd., H1 2013 25
Seattle Genetics, Inc., H1 2013 26
Emergent BioSolutions Inc., H1 2013 27
Novartis AG, H1 2013 28
Eisai Co., Ltd., H1 2013 29
Onyx Pharmaceuticals, Inc., H1 2013 30
Mundipharma International Limited, H1 2013 31
Innate Pharma SA, H1 2013 32
Spectrum Pharmaceuticals, Inc., H1 2013 33
Mondobiotech Holding AG, H1 2013 34
Yaupon Therapeutics, Inc., H1 2013 35
ELORAC, Inc., H1 2013 36
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Stage and Molecule Type, H1 2013 43
Cutaneous T-Cell Lymphoma Therapeutics - Drug Profile Updates 95
Cutaneous T-Cell Lymphoma Therapeutics - Discontinued Products 125
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products 126
Cutaneous T-Cell Lymphoma Therapeutics - Dormant Products (Contd..1) 127

List of Figures


Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2013 10
Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Route of Administration, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Molecule Type, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Physician Dispensed Cosmeceuticals Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018

    By - Transparency

    The global physician dispensed cosmeceuticals market was USD 560 million in 2011 and this market is projected to reach USD1.8 billion by 2018. The market will grow with the compound annual growth rate of 18.15% from 2011 – 2918. Physician dispensed cosmeceuticals market is categorised into product segments such as skin care and eyelash products. The demand for this market will spur due to factors such as product innovations, rise in surgical procedures, increase in consumer spending and growing number of dispensing physicians.  In the current scenario, the market...

  • Benign Prostatic Hyperplasia (BPH) Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy, is a urological disorder that involves proliferation of the cellular components of the prostrate. BPH is the most common form of neoplasm in men. BPH results in the formation of large nodes and nodules in the periurethral region of the prostate. The significantly large nodules compresses the urethral canal that causes to partial or complete urinary tract obstruction which inhibits the normal flow of urine. Obstruction in the urinary tract further leads to complications such as urinary retention, urinary tract infections...

  • PEM Fuel Cells Materials (used for Proton Exchange Membranes and Membrane Electrode Assemblies) Market - Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast, 2012 - 2018

    By - Transparency

    The global market for components of proton exchange membranes (PEM) and membrane electrode assemblies (MEA) used in PEM Fuel cells (PEMFC) is witnessing a trend of rising demand. The market is expected to record a compounded growth of approximately 21.1% from 2012 to 2018. The key factors influencing the market growth are growing environmental problems and depleting conventional fuel resources. This has resulted in the need to find alternative energy resources, and fuel cells have been instrumental in meeting the diverse requirements.  The growing demand for efficient,...